Rangeley Capital LLC Sells 26,000 Shares of Septerna, Inc. $SEPN

Rangeley Capital LLC reduced its holdings in shares of Septerna, Inc. (NASDAQ:SEPN) by 39.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,800 shares of the company’s stock after selling 26,000 shares during the quarter. Rangeley Capital LLC’s holdings in Septerna were worth $956,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in SEPN. Deutsche Bank AG lifted its position in Septerna by 5.3% in the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock valued at $415,000 after acquiring an additional 744 shares in the last quarter. Global Retirement Partners LLC acquired a new position in Septerna during the 4th quarter valued at about $35,000. JPMorgan Chase & Co. increased its holdings in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after purchasing an additional 1,315 shares in the last quarter. PharVision Advisers LLC increased its holdings in Septerna by 17.5% during the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after purchasing an additional 1,780 shares in the last quarter. Finally, Nuveen LLC raised its stake in shares of Septerna by 7.7% in the fourth quarter. Nuveen LLC now owns 25,798 shares of the company’s stock worth $719,000 after purchasing an additional 1,837 shares during the last quarter.

Insiders Place Their Bets

In other Septerna news, insider Samira Shaikhly sold 2,178 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.18, for a total value of $76,622.04. Following the completion of the transaction, the insider owned 793 shares in the company, valued at $27,897.74. This represents a 73.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Daniel D. Long sold 3,333 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $34.36, for a total value of $114,521.88. Following the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at approximately $3,312,716.32. This represents a 3.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 44,494 shares of company stock worth $1,469,391 over the last quarter. 5.80% of the stock is currently owned by corporate insiders.

Septerna Stock Performance

NASDAQ:SEPN opened at $33.10 on Monday. Septerna, Inc. has a 52 week low of $10.62 and a 52 week high of $38.04. The firm has a 50-day moving average price of $32.91 and a two-hundred day moving average price of $28.30. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -40.86 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, May 11th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. The firm had revenue of $26.52 million for the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. As a group, sell-side analysts forecast that Septerna, Inc. will post -1.59 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Raymond James Financial raised their target price on Septerna from $47.00 to $53.00 and gave the company a “strong-buy” rating in a report on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Septerna in a research note on Wednesday, July 1st. Guggenheim cut their price objective on shares of Septerna from $52.00 to $45.00 and set a “buy” rating on the stock in a report on Wednesday, July 1st. Finally, Stifel Nicolaus began coverage on shares of Septerna in a research note on Friday, May 1st. They issued a “buy” rating and a $43.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.89.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.